In The News Posted November 12, 2021 Share Posted November 12, 2021 NEW YORK, Nov. 12, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced that data highlighting an anti-HER2 antibody radiation...View the full article Quote Link to comment Share on other sites More sharing options...
Recommended Posts